Mineralys Therapeutics Financials - Benzinga

Mineralys Therapeutics Inc

MLYSNASDAQ

Trade with Public

Trade with Public

$25.89

-1.00-3.72%

Últ. Act.: Sep 24, 11:50 AM

Panorámica general Noticias Previsión de beneficios Eventos Precios objetivoFinanzasSentimiento Propiedad Comparar Opciones Informe de acciones

Mineralys Therapeutics Financials

Mineralys Therapeutics (MLYS) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Mineralys Therapeutics Q2 EPS $(2.85) Misses $(0.55) Estimate

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Mineralys Therapeutics Q1 EPS $(0.47), Inline

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from the same period last

Benzinga Newsdesk

PRO
Mineralys Therapeutics Q4 EPS $(0.40) Beats $(0.58) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.58) by 30.68 percent. This is a 59.18 percent increase over losses of $(0.98) per share

Benzinga Newsdesk

Earnings Scheduled For March 12, 2026

Benzinga Insights

PRO
Mineralys Therapeutics Q3 EPS $(0.52) Beats $(0.65) Estimate

Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.65) by 19.38 percent. This is a 53.98 percent increase over losses of $(1.13) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved